Current Report Filing (8-k)
September 07 2018 - 5:31PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 or 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): September 6, 2018
Rennova
Health, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
001-35141
|
|
68-0370244
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification No.)
|
400
S. Australian Avenue, Suite 800, West Palm Beach,
Florida
|
|
33401
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(561)
855-1626
|
(Registrant’s
Telephone Number, Including Area Code)
|
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 3.02. Unregistered
Sales of Equity Securities.
As previously announced,
the Additional Issuance Agreements entered into by Rennova Health, Inc. (the “Company”) on July 16, 2018 provided
that, from time to time on or before December 31, 2018, in one or more closings, the Company may request that the institutional
investors party to the Additional Issuance Agreements purchase up to $3,100,000 aggregate principal amount of additional Senior
Secured Original Issue Discount Convertible Debentures due September 19, 2019, issuable under the Additional Issuance Agreements.
As also previously announced, on August 2, 2018 the institutional investors purchased $620,000 aggregate principal amount
of additional Debentures and the Company received proceeds of $500,000.
The Company requested
that the institutional investors purchase a further $1,240,000 aggregate principal amount of Debentures, which was accepted
by the investors. The Debentures were issued on September 6, 2018 and the Company received proceeds of $1,000,000. After the
issuances on August 2, 2018 and September 6, 2018, under the Additional Issuance Agreements the Company may now request that the
institutional investors purchase up to $1,240,000 aggregate principal amount of additional Debentures on or before December 31,
2018.
These Debentures were
issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended,
and by Rule 506 of Regulation D promulgated thereunder as a transaction by an issuer not involving a public offering.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
September 7, 2018
|
RENNOVA
HEALTH, INC.
|
|
|
|
|
By:
|
/s/
Seamus Lagan
|
|
|
Seamus
Lagan
|
|
|
Chief
Executive Officer
|
|
|
(principal
executive officer)
|